FDA approves Watson's generic version of Teva's Plan B

Watson said Friday that the FDA approved its generic version of Teva's progestin-only emergency contraceptive Plan B One-Step (levonorgestrel).

Watson indicated that it will launch the product, which is indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure, under the name Next Choice One Dose immediately. Plan B One-Step generated US sales of $88 million for the 12 months ended May 31.

To read more Top Story articles, click here.